Sana Biotechnology, Inc (SANA)

Etorro trading 970x250

About Sana Biotechnology, Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington. Address: 188 East Blaine Street, Seattle, WA, United States, 98020

Sana Biotechnology, Inc News and around…

Latest news about Sana Biotechnology, Inc (SANA) common stock and company :

Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates
08 Nov, 2021 Yahoo! Finance

Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs Q3 2021 cash position of $866.1 million SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the third quarter of 2021. “We continue to make progress in building the company, progressing our pipeline, and growi

Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
04 Nov, 2021 Yahoo! Finance

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during four poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held both in person in Atlanta, GA and virtually from Sunday, December 11 to Tuesday, December 14, 2021. “We are excited to share data at ASH that showcase scientific advancemen

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology
19 Oct, 2021 FinancialContent

Sana Biotechnology Inc(NASDAQ: SANA)has secured non-exclusive commercial rightstoBeam Therapeutics ...

Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
19 Oct, 2021 Yahoo! Finance

Agreement combines Beam’s gene editing technology with Sana’s ex vivo platform SEATTLE, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with Beam Therapeutics Inc. (NASDAQ: BEAM) for non-exclusive commercial rights to Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs. Cas12b is a CRISPR-based nucl

Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
13 Oct, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.

Add Up The Parts: XBI Could Be Worth $215
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $215.11 per unit.

Notable Sana Biotechnology Insider Trades $1.68 Million In Company Stock
13 Sep, 2021 Yahoo! Finance

Christian Hordo, EVP And Chief Business Officer at Sana Biotechnology (NASDAQ:SANA), made a large buy and sell of company shares on September 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 9, Christian Hordo bought 39,205 Sana Biotechnology shares at a price of $1.48 per share, for a total of $58,023. They then sold their shares on the same day in the open market at a price of $25.01 to raise a total of

Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
07 Sep, 2021 FinancialContent
Calculating The Fair Value Of Sana Biotechnology, Inc. (NASDAQ:SANA)
02 Sep, 2021 Yahoo! Finance

Today we will run through one way of estimating the intrinsic value of Sana Biotechnology, Inc. ( NASDAQ:SANA ) by...

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology
09 Aug, 2021 Yahoo! Finance

MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.

Analysts Anticipate LABU Will Reach $97
05 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $96.81 per unit.

Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates
04 Aug, 2021 FinancialContent
Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg
04 Aug, 2021 FinancialContent

SoftBank Group Corp(OTC: SFTBF) has quietly acquired a $5 billion stake inRoche Holdings AG(OTC: RHHBF), making it ...

Sana Biotech To Establish Manufacturing Facility For Gene, Cell Therapy Candidates
15 Jul, 2021 FinancialContent

Sana Biotechnology Inc(NASDAQ: SANA)has entered into a lease agreementto develop a 163,000 square foot ...

Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates
14 Jul, 2021 FinancialContent
2 Biotech IPO Stocks You'll Want to Have on Your Radar
11 Jul, 2021 FinancialContent

They have promising pipeline candidates and should go public soon.

Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates
26 Jun, 2021 FinancialContent
Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates
26 Jun, 2021 Yahoo! Finance

First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression Transplanting allogeneic cells into a primate without immune suppression represents a key step toward widespread treatment of disease using engineered cells SEATTLE, June 26, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today presented data showi

Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative
14 Jun, 2021 Yahoo! Finance

Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.

Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
14 Jun, 2021 FinancialContent
Add Up The Parts: IWF Could Be Worth $290
04 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 1000 Growth ETF (IWF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $290.14 per unit.

Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
02 Jun, 2021 FinancialContent
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture
25 May, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, today announced the closing of a Series C financing round totaling $88.9 million. Joining founder and principal backer Flagship Pioneering is Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments, and others. With this financing, Invaio has raised more than $142 million since its founding in 2018.

Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening
19 May, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, announced today an agreement with the world-renowned Fundecitrus, Fund for Citrus Protection, located in Araraquara, Brazil. The agreement focuses on the collaboration to evaluate the use of a novel natural peptide to control the devastating disease Citrus Greening (HLB) in Brazilian citrus trees.

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
07 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
06 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

70 Biggest Movers From Yesterday
06 May, 2021 FinancialContent

Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares surged 135.3% to close at $11.06 on Wednesday after the company receipt of a ...

Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates
05 May, 2021 FinancialContent
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
05 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Sana Biotechnology to Present at the BofA Securities 2021 Healthcare Conference
04 May, 2021 FinancialContent

Sana Biotechnology, Inc (SANA) is a NASDAQ Common Stock listed in , ,

970x250